Published in Arch Gen Psychiatry on August 01, 2007
The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact Funct Neurosurg (2009) 2.24
Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull (2008) 0.85
Changes in physician antipsychotic prescribing preferences, 2002-2007. Psychiatr Serv (2014) 0.84
Antipsychotic prescribing: do conflict of interest policies make a difference? Med Care (2015) 0.77
Clozapine treatment of patients with refractory schizophrenia, concurrent dengue infection and hematological abnormalities: three case reports. Ther Adv Psychopharmacol (2013) 0.75
Gingival pain: an unusual side effect of ziprasidone. BMJ Case Rep (2013) 0.75
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry (2006) 9.44
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry (2006) 1.82
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (2008) 10.20
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (2013) 8.20
Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet (2007) 7.85
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res (2011) 5.39
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet (2012) 4.59
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry (2012) 3.29
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr (2010) 3.09
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry (2006) 3.01
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res (2008) 2.67
Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry (2012) 2.61
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry (2008) 2.53
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull (2010) 2.50
The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum (2007) 2.25
Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry (2011) 2.02
Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol (2008) 2.02
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum (2011) 1.91
Decoding the massive genome of loblolly pine using haploid DNA and novel assembly strategies. Genome Biol (2014) 1.90
Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry (2012) 1.85
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) (2005) 1.82
The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol (2011) 1.82
Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum (2007) 1.76
Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry (2007) 1.75
The choice of drugs for schizophrenia. N Engl J Med (2006) 1.75
In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci U S A (2005) 1.72
Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther (2010) 1.63
Maintaining informed consent validity during lengthy research protocols. IRB (2008) 1.62
Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry (2005) 1.57
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry (2002) 1.55
Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology (2006) 1.53
Evolution of genome size and complexity in Pinus. PLoS One (2009) 1.52
Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology (2009) 1.47
The use of depot medications in the treatment of schizophrenia. Am J Psychiatry (2010) 1.43
Priming defense genes and metabolites in hybrid poplar by the green leaf volatile cis-3-hexenyl acetate. New Phytol (2008) 1.40
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull (2006) 1.35
Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res (2007) 1.34
Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology (2007) 1.34
Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2013) 1.30
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull (2006) 1.30
Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev (2012) 1.29
Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull (2009) 1.27
Attenuated psychosis syndrome in DSM-5. Schizophr Res (2013) 1.24
At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull (2012) 1.24
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr Res (2013) 1.21
Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology (2012) 1.21
Catatonia in the DSM--shall we move or not? Schizophr Bull (2009) 1.20
"Just the facts": meandering in schizophrenia's many forests. Schizophr Res (2011) 1.18
S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. Neuroreport (2007) 1.17
Structure of the psychotic disorders classification in DSM-5. Schizophr Res (2013) 1.16
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res (2013) 1.16
High levels of depressive symptoms in pregnancy with low omega-3 fatty acid intake from fish. Epidemiology (2009) 1.16
Rheumatoid arthritis and cardiovascular disease. Am Heart J (2013) 1.14
Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses (2012) 1.12
Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. Biol Psychiatry (2010) 1.11
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res (2009) 1.11
Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull (2014) 1.11
Another view of therapy for cognition in schizophrenia. Biol Psychiatry (2002) 1.11
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol (2003) 1.10
Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry (2004) 1.09
Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv (2005) 1.09
All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol (2007) 1.07
Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol (2010) 1.04
Transcript profiles of the cytokinin response regulator gene family in Populus imply diverse roles in plant development. New Phytol (2007) 1.03
Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract (2002) 1.03
Performance of a self-report measure of the level of response to alcohol in 12- to 13-year-old adolescents. J Stud Alcohol (2005) 1.02
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci (2012) 1.02
The cytokinin type-B response regulator PtRR13 is a negative regulator of adventitious root development in Populus. Plant Physiol (2009) 1.02
White matter alterations in deficit schizophrenia. Neuropsychopharmacology (2008) 1.02
Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res (2012) 1.01
DSM-5 status of psychotic disorders: 1 year prepublication. Schizophr Bull (2012) 1.01
Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis (2010) 1.01
Association mapping of quantitative disease resistance in a natural population of loblolly pine (Pinus taeda L.). Genetics (2010) 1.00
Changing trends in pediatric antipsychotic use in Florida's Medicaid program. Psychiatr Serv (2008) 1.00
MicroRNA expression in rat brain exposed to repeated inescapable shock: differential alterations in learned helplessness vs. non-learned helplessness. Int J Neuropsychopharmacol (2011) 1.00
Optimistic bias in the perception of personal risk: patterns in schizophrenia. Am J Psychiatry (2005) 1.00
Considerations regarding neuropsychiatric nutritional requirements for intakes of omega-3 highly unsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids (2009) 1.00
Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep (2010) 1.00
Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol (2011) 0.99
Nonflowering plants possess a unique folate-dependent phenylalanine hydroxylase that is localized in chloroplasts. Plant Cell (2010) 0.99
Whole-exome targeted sequencing of the uncharacterized pine genome. Plant J (2013) 0.99
Reelin down-regulation in mice and psychosis endophenotypes. Neurosci Biobehav Rev (2006) 0.99
The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry (2004) 0.98
The performance of elements of a 'level of response to alcohol'-based model of drinking behaviors in 13-year-olds. Addiction (2008) 0.98
Lower number of cerebellar Purkinje neurons in psychosis is associated with reduced reelin expression. Proc Natl Acad Sci U S A (2010) 0.97
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry (2003) 0.96
Genetic dissection of fusiform rust and pitch canker disease traits in loblolly pine. Theor Appl Genet (2005) 0.95
Schizoaffective Disorder in the DSM-5. Schizophr Res (2013) 0.95
Testing a level of response to alcohol-based model of heavy drinking and alcohol problems in 1,905 17-year-olds. Alcohol Clin Exp Res (2011) 0.95
Methodological factors influencing measurement and processing of plasma reelin in humans. BMC Biochem (2003) 0.95
Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Compr Psychiatry (2011) 0.95